Description: Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Home Page: www.celularity.com
CELU Technical Analysis
170 Park Avenue
Florham Park,
NJ
07932
United States
Phone:
908 768 2170
Officers
| Name | Title |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, CEO & Chairman |
| Mr. John R. Haines | Sr. EVP, GM & Chief Admin. Officer |
| Mr. David C. Beers C.F.A., CFA | Chief Financial Officer |
| Dr. Bradley Glover Ph.D. | Exec. VP & COO |
| Mr. Tim Wilk | Sr. VP of Technical Operations |
| Carlos Ramirez | SVP of Investor Relations |
| Mr. Keary R. Dunn Esq. | EVP, Gen. Counsel, Chief Legal Officer & Head of Bus. Devel. |
| Ms. Beth Steinbrenner | Exec. VP of HR |
| Dr. Stephen A. Brigido D.P.M. | Pres of Degenerative Diseases |
| Dr. Anne Jones Ph.D. | Exec. VP & Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.0622 |
| Price-to-Book MRQ: | 1.3244 |
| Price-to-Sales TTM: | 11.6308 |
| IPO Date: | 2019-08-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 225 |